Replimune (REPL) Income towards Parent Company (2017 - 2026)

Replimune (REPL) reported Income towards Parent Company of -$73.2 million for Q1 2026, up 1.34% on a YoY basis from -$72.2 million in Q1 2025, and down 3.14% sequentially from -$70.9 million in Q4 2025.

Replimune (REPL) Income towards Parent Company (2017 - 2026) Analysis & Trends

Replimune (REPL) has 10 years of Income towards Parent Company data on file, last reported at -$73.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Income towards Parent Company rose 1.34% year-over-year to -$73.2 million; the trailing twelve-month figure through Mar 2026 stood at -$395.8 million (down 60.01% YoY), and the FY2026 full-year result was -$313.9 million, down 26.91% from the prior year.
  • Income towards Parent Company slipped to -$73.2 million in Q1 2026, from -$70.9 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$31.6 million in Q1 2022 to a low of -$128.7 million in Q2 2025.
  • A 5-year average of -$62.6 million and a median of -$53.8 million in 2024 frame the typical range for Income towards Parent Company.
  • Across the five-year window, Income towards Parent Company soared 51.52% in 2022 and slumped 139.39% in 2025, its largest moves.
  • Tracing REPL's Income towards Parent Company over 5 years: stood at -$39.7 million in 2022, then slipped by 28.8% to -$51.1 million in 2023, then decreased by 29.77% to -$66.3 million in 2024, then decreased by 6.94% to -$70.9 million in 2025, then dropped by 3.14% to -$73.2 million in 2026.
  • Business Quant data shows REPL's Income towards Parent Company at -$73.2 million in Q1 2026, -$70.9 million in Q4 2025, and -$122.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,831.58 Bn 66,831.30 Bn -
2 Nanobiotix 1,916.61 Bn 1,916.55 Bn -
3 Akari Therapeutics 976.78 Bn 976.78 Bn -
4 BeOne Medicines 471.48 Bn 466.69 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.78 Bn 114.53 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn
7 Belite Bio 63.06 Bn 63.06 Bn -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.54 Bn 34.53 Bn 959.66 Mn
10 Replimune 806.93 Mn 806.93 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -73.17 Mn
Dec 31, 2025 -70.94 Mn
Sep 30, 2025 -122.92 Mn
Jun 30, 2025 -128.72 Mn
Mar 31, 2025 -74.16 Mn
Dec 31, 2024 -66.34 Mn
Sep 30, 2024 -53.06 Mn
Jun 30, 2024 -53.77 Mn
Mar 31, 2024 -55.08 Mn
Dec 31, 2023 -51.12 Mn
Sep 30, 2023 -60.04 Mn
Jun 30, 2023 -49.56 Mn
Mar 31, 2023 -49.25 Mn
Dec 31, 2022 -39.69 Mn
Sep 30, 2022 -43.10 Mn
Jun 30, 2022 -42.25 Mn
Mar 31, 2022 -31.62 Mn
Dec 31, 2021 -81.86 Mn
Sep 30, 2021 -82.05 Mn
Jun 30, 2021 -80.79 Mn